Siren LLC’s Crescent Biopharma CBIO Stock Holding History

Siren LLC’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-19,651	Closed	-$332K	–	122
2024 Q3	$332K	Buy	+19,651	New	+$412K	0.02%	108

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Siren LLC's CBIO Position: Q4 2024 in Review

Siren LLC sold out of Crescent Biopharma (CBIO) in Q4 2024, closing a stake of 19,651 shares — an estimated $332K sold.

Siren LLC first reported a position in CBIO in Q3 2024 and held it in 1 quarter. The position peaked at $332K in Q3 2024. 41 funds tracked by Wall St. Rank hold CBIO as of Q4 2024.

Siren LLC reported no remaining Crescent Biopharma position as of Q4 2024 after selling out during the quarter.
Siren LLC sold 19,651 Crescent Biopharma shares in Q4 2024, an estimated $332K.
Siren LLC first reported a position in Crescent Biopharma in Q3 2024 and held it in 1 quarter.
Siren LLC's Crescent Biopharma position peaked at $332K in Q3 2024.
41 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2024.

Based on Siren LLC's 13F filing for Q4 2024, filed 14 Feb 2025.